keyword
MENU ▼
Read by QxMD icon Read
search

HIV Vaccine

keyword
https://www.readbyqxmd.com/read/29226015/conserved-hiv-epitopes-for-an-effective-hiv-vaccine
#1
Bikash Sahay, Cuong Q Nguyen, Janet K Yamamoto
Despite major advances in antiretroviral therapy against HIV-1, an effective HIV vaccine is urgently required to reduce the number of new cases of HIV infections in the world. Vaccines are the ultimate tool in the medical arsenal to control and prevent the spread of infectious diseases such as HIV/AIDS. Several failed phase-IIb to -III clinical vaccine trials against HIV-1 in the past generated a plethora of information that could be used for better designing of an effective HIV vaccine in the future. Most of the tested vaccine candidates produced strong humoral responses against the HIV proteins; however, failed to protect due to: 1) the low levels and the narrow breadth of the HIV-1 neutralizing antibodies and the HIV-specific antibody-dependent Fc-mediated effector activities, 2) the low levels and the poor quality of the anti-HIV T-cell responses, and 3) the excessive responses to immunodominant non-protective HIV epitopes, which in some cases blocked the protective immunity and/or enhanced HIV infection...
August 2017: Journal of Clinical & Cellular Immunology
https://www.readbyqxmd.com/read/29226013/novel-therapeutic-approach-for-inhibition-of-hiv-1-using-cell-penetrating-peptide-and-bacterial-toxins
#2
Steven Samuels, Zainab Alwan, Marceline Egnin, Jessie Jaynes, Terry D Connell, Gregory C Bernard, Toufic Nashar
Despite advancements in our understanding of HIV-1 pathogenesis, critical virus components for immunity, vaccines trials, and drugs development, challenges remain in the fight against HIV-1. Of great importance is the inhibitory function of microbicidal cell penetrating peptides and bacterial toxins that interfere with production and neutralize infection of HIV-1 particles. We demonstrate that the neutralizing activity of a cationic 18 amino acids peptide, is similar to a broadly neutralizing human antibody, and inhibits production of two HIV-1 strains in human cell lines...
October 2017: Journal of AIDS & Clinical Research
https://www.readbyqxmd.com/read/29224963/meeting-report-initial-world-health-organization-consultation-on-herpes-simplex-virus-hsv-vaccine-preferred-product-characteristics-march-2017
#3
Sami L Gottlieb, Birgitte K Giersing, Julian Hickling, Rebecca Jones, Carolyn Deal, David C Kaslow
The development of vaccines against herpes simplex virus (HSV) is an important global goal for sexual and reproductive health. A key priority to advance development of HSV vaccines is the definition of preferred product characteristics (PPCs), which provide strategic guidance on World Health Organization (WHO) preferences for new vaccines, specifically from a low- and middle-income country (LMIC) perspective. To start the PPC process for HSV vaccines, the WHO convened a global stakeholder consultation in March 2017, to define the priority public health needs that should be addressed by HSV vaccines and discuss the key considerations for HSV vaccine PPCs, particularly for LMICs...
December 7, 2017: Vaccine
https://www.readbyqxmd.com/read/29224404/edip-the-epitope-dilution-phenomenon-lessons-learnt-from-a-malaria-vaccine-antigen-and-its-applicability-to-polymorphic-antigens
#4
Kwadwo Asamoah Kusi, Bart W Faber, Gerrit Koopman, Edmond Joseph Remarque
Polymorphism in vaccine antigens poses major challenges to vaccinologists. The Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) poses such a challenge. We found that immunization with a mixture of three variants yielded functional antibody levels to all variants comparable to levels induced by monovalent immunization. The mechanism behind the observed broadening was shown to be an increase in the fraction of cross-reactive antibodies, most likely because strain-specific epitopes are present at lower frequency relative to conserved epitopes...
December 11, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/29222332/stabilization-of-the-gp120-v3-loop-through-hydrophobic-interactions-reduces-the-immunodominant-v3-directed-non-neutralizing-response-to-hiv-1-envelope-trimers
#5
Steven W de Taeye, Alba Torrents de la Peña, Andrea Vecchione, Enzo Scutigliani, Kwinten Sliepen, Judith A Burger, Patricia van der Woude, Anna Schorcht, Edith E Schermer, Marit J van Gils, Celia C LaBranche, David C Montefiori, Ian A Wilson, John P Moore, Andrew B Ward, Rogier W Sanders
To provide protective immunity against circulating primary HIV-1 strains, a vaccine most likely has to induce broadly neutralizing antibodies (bNAbs) to the HIV-1 envelope (Env) glycoprotein spike. Recombinant Env trimers such as the prototype BG505 SOSIP.664 that closely mimic the native Env spike can induce autologous neutralizing antibodies (NAbs) against relatively resistant (tier-2) primary viruses. Ideally, Env immunogens should present bNAb epitopes, but limit the presentation of immunodominant non-NAb epitopes that might induce off-target and potentially interfering responses...
December 8, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29220358/minimally-invasive-monitoring-of-cd4-t-cells-at-multiple-mucosal-tissues-after-intranasal-vaccination-in-rhesus-macaques
#6
Stephanie Dorta-Estremera, Pramod N Nehete, Guojun Yang, Hong He, Bharti P Nehete, Kathryn K Shelton, Michael A Barry, K Jagannadha Sastry
Studies in nonhuman primates (NHP) for prospective immune cell monitoring subsequent to infection and/or vaccination usually rely on periodic sampling of the blood samples with only occasional collections of biopsies from mucosal tissues because of safety concerns and practical constraints. Here we present evidence in support of cytobrush sampling of oral, rectal, and genital mucosal tissues as a minimally invasive approach for the phenotypic analyses of different T cells subsets de novo as well as prospectively after intranasal immunization in rhesus macaques...
2017: PloS One
https://www.readbyqxmd.com/read/29218117/basis-and-statistical-design-of-the-passive-hiv-1-antibody-mediated-prevention-amp-test-of-concept-efficacy-trials
#7
Peter B Gilbert, Michal Juraska, Allan C deCamp, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Deborah J Donnell, Carter Bentley, Nirupama Sista, Philip Andrew, Abby Isaacs, Yunda Huang, Lily Zhang, Edmund Capparelli, Nidhi Kochar, Jing Wang, Susan H Eshleman, Kenneth H Mayer, Craig A Magaret, John Hural, James G Kublin, Glenda Gray, David C Montefiori, Margarita M Gomez, David N Burns, Julie McElrath, Julie Ledgerwood, Barney S Graham, John R Mascola, Myron Cohen, Lawrence Corey
Background: Anti-HIV-1 broadly neutralizing antibodies (bnAbs) have been developed as potential agents for prevention of HIV-1 infection. The HIV Vaccine Trials Network and the HIV Prevention Trials Network are conducting the Antibody Mediated Prevention (AMP) trials to assess whether, and how, intravenous infusion of the anti-CD4 binding site bnAb, VRC01, prevents HIV-1 infection. These are the first test-of-concept studies to assess HIV-1 bnAb prevention efficacy in humans. Methods: The AMP trials are two parallel phase 2b HIV-1 prevention efficacy trials conducted in two cohorts: 2700 HIV-uninfected men and transgender persons who have sex with men in the United States, Peru, Brazil, and Switzerland; and 1500 HIV-uninfected sexually active women in seven countries in sub-Saharan Africa...
January 2017: Statistical Communications in Infectious Diseases
https://www.readbyqxmd.com/read/29218036/the-macrophage-a-disputed-fortress-in-the-battle-against-mycobacterium-tuberculosis
#8
REVIEW
Christophe J Queval, Roland Brosch, Roxane Simeone
Mycobacterium tuberculosis (Mtb), the etiological agent of human tuberculosis (TB), has plagued humans for thousands of years. TB still remains a major public health problem in our era, causing more than 4,400 deaths worldwide every day and killing more people than HIV. After inhaling Mtb-contaminated aerosols, TB primo-infection starts in the terminal lung airways, where Mtb is taken up by alveolar macrophages. Although macrophages are known as professional killers for pathogens, Mtb has adopted remarkable strategies to circumvent host defenses, building suitable conditions to survive and proliferate...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29217414/yellow-fever-vaccine-for-people-living-with-hiv-infection
#9
Lesley Andrews
No abstract text is available yet for this article.
December 4, 2017: Journal of the Association of Nurses in AIDS Care: JANAC
https://www.readbyqxmd.com/read/29216355/prevalence-of-and-risk-factors-for-anal-hpv-among-a-sample-of-predominantly-black-men-who-have-sex-with-men-in-houston-texas
#10
Alan G Nyitray, Kayo Fujimoto, Jing Zhao, Anna R Giuliano, John A Schneider, Lu-Yu Hwang
Introduction: Young men who have sex with men (MSM) are at increased risk for human papillomavirus (HPV)-associated disease as a result of HPV infection. Our objective was to characterize high-risk anal HPV prevalence, and factors associated with prevalence, among a group of young, primarily black, MSM in Houston, Texas. Background: Young MSM, aged 18-29 years, were recruited using a respondent-driven sampling method to study HIV/STD transmission and risk. The current analysis estimated HPV prevalence among 135 primarily young black MSM who engaged in peer recruitment chains and who self-collected anal exfoliated cells...
December 5, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29216183/presentation-of-life-threatening-invasive-nontyphoidal-salmonella-disease-in-malawian-children-a-prospective-observational-study
#11
Calman A MacLennan, Chisomo L Msefula, Esther N Gondwe, James J Gilchrist, Paul Pensulo, Wilson L Mandala, Grace Mwimaniwa, Meraby Banda, Julia Kenny, Lorna K Wilson, Amos Phiri, Jenny M MacLennan, Elizabeth M Molyneux, Malcolm E Molyneux, Stephen M Graham
Nontyphoidal Salmonellae commonly cause invasive disease in African children that is often fatal. The clinical diagnosis of these infections is hampered by the absence of a clear clinical syndrome. Drug resistance means that empirical antibiotic therapy is often ineffective and currently no vaccine is available. The study objective was to identify risk factors for mortality among children presenting to hospital with invasive Salmonella disease in Africa. We conducted a prospective study enrolling consecutive children with microbiologically-confirmed invasive Salmonella disease admitted to Queen Elizabeth Central Hospital, Blantyre, in 2006...
December 7, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29212716/a-randomized-controlled-safety-efficacy-trial-of-therapeutic-vaccination-in-hiv-infected-individuals-who-initiated-antiretroviral-therapy-early-in-infection
#12
Michael C Sneller, J Shawn Justement, Kathleen R Gittens, Mary E Petrone, Katherine E Clarridge, Michael A Proschan, Richard Kwan, Victoria Shi, Jana Blazkova, Eric W Refsland, Daryl E Morris, Kristen W Cohen, M Juliana McElrath, Rong Xu, Michael A Egan, John H Eldridge, Erika Benko, Colin Kovacs, Susan Moir, Tae-Wook Chun, Anthony S Fauci
Despite substantial clinical benefits, complete eradication of HIV has not been possible using antiretroviral therapy (ART) alone. Strategies that can either eliminate persistent viral reservoirs or boost host immunity to prevent rebound of virus from these reservoirs after discontinuation of ART are needed; one possibility is therapeutic vaccination. We report the results of a randomized, placebo-controlled trial of a therapeutic vaccine regimen in patients in whom ART was initiated during the early stage of HIV infection and whose immune system was anticipated to be relatively intact...
December 6, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/29212710/clinical-trial-design-the-nobility-of-randomization
#13
REVIEW
Nelson L Michael
A clinical trial evaluating HIV vaccine therapy teaches us much about optimal design (Sneller et al, this issue).
December 6, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/29212041/soluble-prefusion-closed-ds-sosip-664-env-trimers-of-diverse-hiv-1-strains
#14
M Gordon Joyce, Ivelin S Georgiev, Yongping Yang, Aliaksandr Druz, Hui Geng, Gwo-Yu Chuang, Young Do Kwon, Marie Pancera, Reda Rawi, Mallika Sastry, Guillaume B E Stewart-Jones, Angela Zheng, Tongqing Zhou, Misook Choe, Joseph G Van Galen, Rita E Chen, Christopher R Lees, Sandeep Narpala, Michael Chambers, Yaroslav Tsybovsky, Ulrich Baxa, Adrian B McDermott, John R Mascola, Peter D Kwong
The elicitation of autologous neutralizing responses by immunization with HIV-1 envelope (Env) trimers conformationally stabilized in a prefusion closed state has generated considerable interest in the HIV-1 vaccine field. However, soluble prefusion closed Env trimers have been produced from only a handful of HIV-1 strains, limiting their utility as vaccine antigens and B cell probes. Here, we report the engineering from 81 HIV-1 strains of soluble, fully cleaved, prefusion Env trimers with appropriate antigenicity...
December 5, 2017: Cell Reports
https://www.readbyqxmd.com/read/29211629/report-of-the-fifth-european-expert-meeting-on-rotavirus-vaccination-eerovac-utrecht-the-netherlands-20-22-march-2017
#15
Marieke L A de Hoog, Timo Vesikari, Carlo Giaquinto, Hans-Iko Huppertz, Federico Martinon-Torres, Patricia Bruijning-Verhagen
The Fifth European Expert Meeting on Rotavirus Vaccination was convened in Utrecht, The Netherlands, in March 2017. The 2-day meeting included invited lectures as well as original oral and poster presentations and brought together experts from 21 countries. Summary findings of the meeting include: Rotavirus vaccination programmes in Europe have resulted in reductions of 60-90% in rotavirus outpatient visits and hospitalizations. Long term trends indicate this impact is sustained over the years. Herd effects, protecting unvaccinated children and neonates too young to be vaccinated have been observed in many European countries...
December 6, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29210158/screening-for-human-papillomavirus-cervical-cytological-abnormalities-and-associated-risk-factors-in-hiv-positive-and-hiv-negative-women-in-rwanda
#16
M F Mukanyangezi, V Sengpiel, O Manzi, G Tobin, S Rulisa, E Bienvenu, D Giglio
OBJECTIVES: Cervical cancer is the major cause of death from cancer in Africa. We wanted to assess the prevalence of human papillomavirus (HPV) infections and associated risk factors and to determine whether HPV testing could serve as a screening method for squamous intraepithelial lesions (SILs) in Rwanda. We also wanted to obtain a broader understanding of the underlying risk factors for the establishment of HPV infection in Rwanda. METHODS: A total of 206 HIV-positive women, 172 HIV-negative women and 22 women with unknown HIV status were recruited at the University Teaching Hospitals of Kigali (UTHK) and of Butare (UTHB) in Rwanda...
December 6, 2017: HIV Medicine
https://www.readbyqxmd.com/read/29209323/non-neutralizing-antibodies-directed-against-hiv-and-their-functions
#17
REVIEW
Luzia M Mayr, Bin Su, Christiane Moog
B cells produce a plethora of anti-HIV antibodies (Abs) but only few of them exhibit neutralizing activity. This was long considered a profound limitation for the enforcement of humoral immune responses against HIV-1 infection, especially since these neutralizing Abs (nAbs) are extremely difficult to induce. However, increasing evidence shows that additional non-neutralizing Abs play a significant role in decreasing the viral load, leading to partial and sometimes even total protection. Mechanisms suspected to participate in protection are numerous...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29208161/hepatitis-a-outbreak-in-hiv-infected-msm-and-in-prep-using-msm-despite-a-high-level-of-immunity-lyon-france-january-to-june-2017
#18
Caroline Charre, Christophe Ramière, Anne-Marie Roque-Afonso, Christian Chidiac, Fabien Zoulim, Matthieu Godinot, Joseph Koffi, Caroline Scholtès, Jean-Michel Livrozet, Hav Lyon Study Group, Laurent Cotte
Since 2016, an increase in the number of hepatitis A cases affecting mainly men who have sex with men (MSM) has been reported in low endemic countries in Europe. We calculated the attack rate in Lyon, France, in populations considered at high-risk: HIV-infected MSM and HIV-negative MSM receiving HIV pre-exposure prophylaxis (PrEP). In these populations, high level of immunity did not prevent the outbreak, indicating that vaccination should be reinforced, particularly in younger individuals.
November 2017: Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles, European Communicable Disease Bulletin
https://www.readbyqxmd.com/read/29207239/the-human-microbiota-infectious-disease-and-global-health-challenges-and-opportunities
#19
Abraham J Waldman, Emily P Balskus
Despite significant advances in treating infectious diseases worldwide, morbidity and mortality associated with these pathogens remains extraordinarily high and represents a critical scientific and global health challenge. Current strategies to combat these infectious agents include a combination of vaccines, small molecule drugs, increased hygiene standards, and disease-specific interventions. While these approaches have helped to drastically reduce the incidence and number of deaths associated with infection, continued investment in current strategies and the development of novel therapeutic approaches will be required to address these global health threats...
December 5, 2017: ACS Infectious Diseases
https://www.readbyqxmd.com/read/29205929/dendritic-cell-targeted-hiv-1-gag-protein-vaccine-provides-help-to-a-recombinant-newcastle-disease-virus-vectored-vaccine-including-mobilization-of-protective-cd8-t-cells
#20
Loveline N Ngu, Nadesh N Nji, Georgia Ambada, Apeh A Ngoh, Ghislain D Njambe Priso, Jules C Tchadji, Abel Lissom, Suzanne H Magagoum, Carol N Sake, Thibau F Tchouangueu, George O Chukwuma, Arinze S Okoli, Bertrand Sagnia, Rebecca Chukwuanukwu, Denis M Tebit, Charles O Esimone, Alain B Waffo, Chae G Park, Klaus Überla, Godwin W Nchinda
INTRODUCTION: Recombinant Newcastle Disease virus (rNDV) vectored vaccines are safe mucosal applicable vaccines with intrinsic immune-modulatory properties for the induction of efficient immunity. Like all viral vectored vaccines repeated inoculation via mucosal routes invariably results to immunity against viral vaccine vectors. To obviate immunity against viral vaccine vectors and improve the ability of rNDV vectored vaccines in inducing T cell immunity in murine air way we have directed dendritic cell targeted HIV-1 gag protein (DEC-Gag) vaccine; for the induction of helper CD4+ T cells to a Recombinant Newcastle disease virus expressing codon optimized HIV-1 Gag P55 (rNDV-L-Gag) vaccine...
December 4, 2017: Immunity, Inflammation and Disease
keyword
keyword
11552
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"